Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Mono Pharmacare Ltd. (MONOPHARMA)
SME CapPharma stocks · SME cap · NSE
Mono Pharmacare Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals20 Oct 2026 · screener
Latest result16 Jul, 06:45 pm IST
Score20 Oct, 04:19 pm IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
63BullishSMA20 -3.3% / mo · MACD + · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 40
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
MONOPHARMAD candles · FIT view-28.8%Latest close ₹8.90 on 2026-10-09
Bar
+5.3%
RSI
52
MACD hist
0.06
52W pos
10%
2026-10-09O ₹8.45H ₹8.90L ₹8.45C ₹8.90Vol 14,000 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
MONOPHARMANifty PharmaNifty 500
- MONOPHARMA
- -16.0%
- Nifty 500
- -6.3%
- Nifty Pharma
- +1.3%
- Vs Nifty 500
- -9.7 pp
Chart stats
9 Oct 2026- From 52W high
- -68.1%
- 52W range position
- 7%
- ATR (14)
- 4.1%
- Volume vs 20D
- 1.82x
- Avg traded value
- ₹0 Cr
- 20D price channel
- ₹8 - ₹9
₹27.9
₹7.5 - ₹27.9
₹0.4
Latest completed session
20-session average
55.5% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED18
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad2
Revenue +76.8% · PAT -100.0% YoY
Technical
Bullish63
Price trend and sector-relative-strength timing.
Valuation
Legacy model-408.4%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence51
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Bad · 2/100PAT -100% YoY · margin compression · Rev +77% YoY · +50% QoQ
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹99 Cr | +76.8% | +50.0% |
| EBITDA | ₹2 Cr | NDF | +0.0% |
| Operating margin | 2.2% | NDF | -50 bps |
| PAT | ₹0 Cr | -100.0% | NDF |
| PAT margin | 0.0% | NDF | +0 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 21.60
- P/B
- 0.50
- EV/EBITDA
- 14.34
- Market Cap
- 15.70Cr
Profitability
- ROE
- 2.33%
- ROCE
- 5.10%
- ROA
- 0.82%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 71.34%
- EPS 5Y
- —
- Revenue 3Y
- 71.00%
- EPS 3Y
- -8.00%
Balance Sheet
- Debt/Equity
- 1.75
- Interest Coverage
- 1.67×
- Altman Z
- 1.86
- Book Value
- 17.90
Cash Flow
- FCF Yield
- 19.11%
- FCF Positive Y
- 1/5
- OCF
- 3.00 Cr
- EPS TTM
- 0.41
Shareholding
- Promoter Hold
- 56.72%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 10%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 166-1.2% vs prev
Net Profit
₹ CrLatest: 1.0-66.7% vs prev
Return on Equity
%Latest: 3.1-66.6% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 52. Wait for confirmation.
- SMA20 falling (~3.4% over last month) — short-term momentum negative.
- RSI(14) at 52 — rising, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 60% off 52W high · 19% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
34
RS percentile
Stage 4 Downtrend
1M return
+2.9%
3M return
-18.7%
6M return
-18.0%
1Y return
-
RS 1D
+14
RS 20D
+31
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 22.1% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -12.1%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
172 observations
09 Oct 2026Value 42.02+3.50%
RS vs Nifty 50042
Valuation & peers
U-Score 18 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 18 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation11/30
Growth6/25
Quality0/20
Balance Sheet2/15
Cash Flow5/10
Piotroski
4/9 (+1)
Penalties
-7
Raw sum
18
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
18/100 · legacy band OVERVALUED
Positive drivers
- FCF yield is supportive at 19.1%.
- Cash flow contributes 5/10 to the score.
- Valuation contributes 11/30 to the score.
Main drags
- Penalty bucket subtracts 7 points.
- Fair-value margin of safety is negative at -408.4%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
21.6
PB
0.5
EV/EBITDA
14.3
ROE
2.3%
ROCE
5.1%
FCF Yield
19.1%
Debt/Equity
1.8
MoS
-408.4%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
18
Previous: 18
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-408.4%
Previous: -408.4%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
18
18
18
18
18
18
18
18
18
18
18
18
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹12.85
+30.7% MoS
Growth-justified P/E
4.3
Growth-justified Value
₹1.75
-408.4% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SUNREST
SME
Sunrest Lifescience Ltd.
Pharmaceuticals
match 164
68
5.5
15.2%
+91%
UNDERVALUED
JFLLIFE
SME
JFL Life Sciences Ltd.
Pharmaceuticals
match 152
69
5.0
15.0%
+89%
UNDERVALUED
ONYX
SME
Onyx Biotec Ltd.
Pharmaceuticals
match 150
15
—
-0.4%
—
OVERVALUED
CURIS
SME
Curis Lifesciences Ltd.
Pharmaceuticals
match 149
33
30.0
—
+57%
WATCHLIST
REMUS
SME
Remus Pharmaceuticals Ltd.
Pharmaceuticals
match 148
44
27.6
12.2%
+30%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Mono Pharmacare Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
51Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 9th percentile of the scored universe and 6th percentile within Pharma. Main check: financial discipline is weak at 10/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
9th percentile
overall median 67 · Pharma: 6th pctile, median 70 · SME: 9th pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
65
acceptable · profit to cash conversion
Balance sheet
39
weak · leverage and solvency
Discipline
10
weak · capital discipline
Results
49
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 56.7%.
- ▸Promoter pledge is zero.
- ▸FCF yield is 12.7%.
- ▸OPM spread across recent quarters is 3.8%.
Trust risks
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸Only 1 years of positive FCF.
- ▸Debt/equity is 1.75.
- ▸Interest coverage is 1.3x.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Mono Pharmacare Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.